Serine hydrolase-targeted therapeutics harnessing the endocannabinoid system to address neurological and pain disorders w. limited or no treatment options. Ph 2: Tourette Syndrome ongoing with data expected in 1Q20; Ph 1b: neuropathic pain complete, with plans to initiate Ph 2 in 1H19.
Phase l or ll, Pre-Clinical Stage
Central Nervous System
10835 Road to the Cure, Suite 250
San Diego, CA 92121
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.